Argitalpenak (10) JOSÉ AGUARELES GORINES argitalpenak

2024

  1. Outcomes and clinical characteristics of the compassionate use of plitidepsin in COVID-19 patients with solid tumours, haematological malignancies or anti-CD20 antibody treatment

    Infectious Diseases, Vol. 56, Núm. 7, pp. 575-580

2023

  1. Erratum: Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019 (Journal of Infectious Diseases (2022) 226 (1, 1-5) DOI: 10.1093/jid/jiac090)

    Journal of Infectious Diseases

  2. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19

    International Journal of Infectious Diseases, Vol. 135, pp. 12-17

  3. Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

    Journal of Hematology and Oncology

2020

  1. Endocannabinoid signalling in stem cells and cerebral organoids drives differentiation to deep layer projection neurons via CB1 receptors

    Development (Cambridge, England), Vol. 147, Núm. 24

  2. Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure

    Neuropsychopharmacology, Vol. 45, Núm. 5, pp. 877-886

2019

  1. Contribution of altered endocannabinoid system to overactive mTORC1 signaling in focal cortical dysplasia

    Frontiers in Pharmacology, Vol. 9, Núm. JAN

  2. Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration

    Translational Neurodegeneration, Vol. 8, Núm. 1

2016

  1. VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease

    Scientific Reports, Vol. 6